Table 3

Window of opportunity: impact of early treatment start on functional and radiographic outcomes

Reference (LoE)Data sourcePopulationnDMARD startEnd pointFunctional outcomesRadiographic outcomes
Bosello et al (2b)24Consecutive patients attending early arthritis clinicRA with duration <12 months44<3 monthsPresence of at least one erosion at 12 months27.1%
77≥3 months45.4%
Gremese et al (2b)25Consecutive patients attending 3 early arthritis clinicsRA with duration <12 months105<3 months12-month HAQ <0.5 62.7%
376≥3 months41.3%
Lukas et al (2b)26ESPOIRArthritis with duration <6 months140<3 months12-month mean radiographic progression0.8 units/year *,†
521≥3 months 1.7 units/year
Weng et al (2b)32Western Consortium of Practicing rheumatologist studyRF+RA within 16 months from symptoms onset to DMARD initiation42<3 months2-year changes in HAQ and mTSS progression−0.63±0.584.62±8.46 units/year
3≥10 months−0.35±0.611.77±2.75 units/year
  • *Comparison early versus late DMARD start: p<0.05.

  • †Propensity analysis. Data are expressed in means±SD or in percentage.

  • DMARD, disease-modifying antirheumatic drug; ESPOIR, Evaluation et Suivi de POlyarthrites Indifférenciées Récentes; HAQ, Health Assessment Questionnaire; LoE, level of evidence; mTSS, modified total Sharp score; RA, rheumatoid arthritis.